Glycomine, Inc. Announces $33 Million Series B Financing to Advance its Therapy for a Congenital Dis

SAN CARLOS, California, Aug. 7, 2019 /PRNewswire/ -- Glycomine, Inc., a biotechnology company focused on developing new therapies for rare diseases, today announced ... Lees verder

Bron:

ANP Pers support